Exciton Technologies has received approval from the China Food and Drug Administration (CFDA) for Exsalt®, the Company’s line of wound care products, using the antimicrobial properties of silver to prevent bacterial growth and the spread of infections.

The registration process was led by MKS Medicine Technology, a Beijing-based medical device company in conjunction with a distribution agreement signed in 2013. MKS will primarily focus on selling to the burn and chronic wound markets in highly populated areas of southeastern China, including Beijing, Guangdong Province and Shanghai. With more than 90 million diabetics and a growing population of elderly people, the need for effective wound care products is high.  CFDA approval expands the global reach for Exciton’s platform Ag Oxysalts™ technology. Sales of Exsalt® dressings could potentially double Exciton’s manufacturing output during the next year.

“Entering the China market means significantly more people suffering with devastating wounds have access to a clinically proven and cost-effective technology,” stated Rod Precht, President & CEO and founder of Exciton Technologies. “The first shipment of Exsalt® dressings has been delivered and positive feedback from doctors is already coming in. And we’re not done yet – we have big plans for developing new products to accelerate our global business strategy.”

MKS Vice President Jason Zhang commented, “the success of CFDA registration attributes to the innovative technology in Exsalt® and our significant industry experience. We believe we have the capabilities and relationships to make Exsalt® one of the few best brands for the wound care industry in China.”

"China is hungry for the products Alberta businesses create in health innovation.  By expanding to new markets Exciton is helping to diversify our economy and create new Alberta opportunities,” shared Minister of Economic Development and Trade, Deron Bilous. 

About Exsalt® 

Exsalt® dressings, containing Exciton’s patented Ag Oxysalts™ technology, are already approved by Health Canada, US Food and Drug Administration (FDA), and CE marked for sale in Europe. The wound dressings have well established infection prevention properties and are now becoming increasingly recognized as an effective treatment for burns and non-healing chronic wounds.

# # #

About Exciton Technologies Inc.

Exciton Technologies is a commercial stage advanced materials development and manufacturing company, based in Edmonton, Alberta focused on the creation of technologies for preventing and treating infection. Exciton has developed a portfolio of proprietary and patented processes to incorporate its silver oxysalts (Ag Oxysalts™) technology into a range of products, including Exsalt® SD7 and T7 dressings, to target the advanced wound care and anti-infectives markets.

Ag Oxysalts™ technology is based on a unique compound containing higher oxidation states of silver (+2 and +3) in comparison to conventional formats (0 and +1). Silver has a long history of safety and efficacy as a topical antibacterial. Exsalt® SD7 and T7 wound dressings incorporating silver oxysalts are demonstrating superior antibacterial activity at a much lower cost than competitive wound dressings. Evidence of superior antibacterial properties leading to improved patient outcomes is steadily increasing across the globe.

Exciton has a license and distribution agreement with UK-based Crawford Healthcare for a line of wound dressings incorporating Ag Oxysalts™ technology initially targeting the US and Europe.  The Company distributes Exsalt® wound dressings through Cardinal Health in Canada.

About MKS Medicine Technology Co., Ltd.

MKS is medical device business established in 2011 and based in Beijing with expertise in market research, product registration with CFDA, and medical device distribution across China. MKS is closely connected with Medfron Medicine Technology Co., Ltd, a publicly listed pharmaceutical company in China with a network of 350 distributors to target more than 1000 large hospitals.

Media Relations:

Stephanie Gillis-Paulgaard
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ph: 780-885-0458

Forward-looking Statements


This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

CTV Edmonton News Carmen Leibel shares Kirstin Hubert's story and speaks of local #yeg exsalt wound dressings by Exciton Technologies - Innovation for clinical options in wound care and burns.   Alberta provincial health care professionals now have access to order the exsalt wound dressings through Alberta Health Services. Any Canadian retail and health centre pharmacy can bring in stock for direct patient purchase through the Canadian national distributor, Cardinal Health Canada 

"Foot ulcers affect an estimated 15 to 25 percent of people with diabetes. For some, amputation is the eventual solution.   Between 2011 and 2012, one-third of amputations in Alberta were performed on people with a diabetic foot wound."

Read about Kirstin Hubert, 38, who was diagnosed with Type 1 diabetes when she was 11 years old, has gastric neuropathy, peripheral neuropathy in her hands and feet.

Read about a dedicated wound nurse, Marlene Varga, who was assigned to care for Hubert, used a new kind of silver bandage,the Exsalt™ wound dressing.   Quoting article, "Exsalt™ contains less silver than other silver bandages, making it safer, less painful, and  less expensive to manufacture.  Another advantage it has over bandages with higher silver content is that it won’t discolour the skin..."  Read why this matters in the patient's  perspective.  

IMG 0321IMAG3575

Read why a local Alberta researched & manufactured wound dressing is not widely available within Alberta Health Services (AHS). 

Read how Alberta Innovates — Health Solutions (AIHS) wants to change that through its new funding program, Accelerating Innovation Into Care (AICE). Working with several partners, including Alberta Health Services’ Strategic Clinical Networks (SCNs) to pave a pathway for adoption.



Startup Canada announced the 2016 Startup Canada Award regional winners. These winners are nation-builders inspiring the next generation of game changers, disruptors, and innovative leaders. They demonstrate that taking risks, disrupting industries, and supporting one another are pathways to a successful future for all Canadians.


Exciton Technologies energies and dedication to advanced the future of wound, burn and infection control globally was proudly awarded at the StartUp Canada Awards 2016.   We are proud to be one of Canada's innovators and entrepreneurs working to build a better tomorrow!  Thank you.



IMG 20161025 222501Screen Shot 2016 10 25 at 10.43.53 PM


Screen Shot 2016 10 25 at 10.54.37 PM

Exciton Technologies Inc., creator of the patented infection-fighting Silver Oxysalts technology, has made a pivotal turn to profitability through expansion of its license agreement with Crawford Healthcare Ltd., the UK's fastest growing wound care company. Exciton has been working with Crawford since 2013 but, following what Crawford calls "a dramatic market response to the use of this patented technology in both the US and the UK," the companies have now expanded to an exclusive global arrangement for a broader range of products. Commenting on the deal, Crawford's Healthcare CEO, Richard Anderson said, "We now have an unrivalled antimicrobial platform to tackle the issue of secondary infections faced by clinicians the world over."

Read full news press release: Expands Global Licensing Agreement and Manufacturing Facilities  March 8, 2016

cover image SD7


Subscribe for Updates

* indicates required